The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/foc.6.2.foc167

The management of new-onset schizophrenia represents an enormous challenge and opportunity. The evaluation and treatment decisions that are implemented at this phase of illness can have an important impact on subsequent course and outcome. It is important to consider factors that are specific to managing first-episode patients when choosing medication, establishing a treatment plan, and evaluating both therapeutic response and potential adverse reactions. Maintenance treatment strategies and approaches to facilitating adherence with clinical recommendations are also important issues in this context.